权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Substrate requirements of the bile acid transporter

胆汁酸转运蛋白的底物要求

基本信息

批准号：
7681114
负责人：
JAMES E POLLI
金额：
$ 29.18万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-10 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7681114
关键词：
3-Dimensional ASBT protein Acyclovir Bile Acid Biosynthesis Pathway Bile Acids Biological Biological Assay Biological Availability Biological Models Biology Carrier Proteins Cell Culture Techniques Cells Charge Chemicals Chemistry Classification Complement Data Data Set Descriptor Development Drug Delivery Systems Evaluation Gastrointestinal tract structure Genetic Glutamic Acid Goals Human In Vitro Intestines Kinetics Knowledge Lead Location Longitudinal Studies Measures Mediating Membrane Membrane Transport Proteins Methods Modeling Molecular Molecular Conformation Molecular Models Nutrient Oral Parents Pattern Pharmaceutical Preparations Physiological Prodrugs Property Proteins Quantitative Structure-Activity Relationship Rattus Research Research Personnel Resolution Role Series Side Structure System Testing Time Xenobiotics absorption analog base bile acid transporter carboxylate design ileum in vivo interdisciplinary approach molecular modeling monolayer novel programs protein structure solute

项目摘要

DESCRIPTION (PROVIDED BY APPLICANT): Several solute carrier proteins (SLC) are expressed in the intestine to absorb nutrients and xenobiotics. In spite of their physiological importance, carrier proteins have not been systematically employed as targets to increase oral drug bioavailability. The current proposal aims to close this gap by focusing on one of the few pharmacologically important transporters in the gastrointestinal tract: the human apical sodium-dependent bile acid transporter (hASBT). hASBT reabsorbs over 12 grams of bile acids daily, suggesting hASBT's tremendous capacity to serve as a drug or prodrug target for absorption. Preliminary data shows that drugs may be conjugated with a bile acid's C-24 carboxylate to yield prodrugs that are translocated by hASBT and increase drug bioavailability. Acyclovir's bioavailability was doubled in rats using a prodrug that targets hASBT. We hypothesize that a systematic structure-activity approach can be used to elucidate the chemistry space of the bile acid's C-24 side chain region that permits bile acid conjugates to be transported by hASBT. The aim of this proposal is to develop a comprehensive and predictive three-dimensional quantitative structure-activity relationship (3D-QSAR) model for the hASBT substrate requirements of bile acid conjugates. 3D-QSAR development will be achieved by synthesizing several congeneric series of bile acid conjugates that systematically span a diverse chemistry space in the C-24 side chain region. Conjugates will be assayed for hASBT-mediated transport and inhibition using in vitro cell culture. A novel molecular modeling approach that considers conformation distribution patterns will be used in 3D-QSAR development. In vivo evaluation of selected bile acid conjugates will be performed in rats, to scale the in vitro 3D-QSAR model to an in vivo 3D-QSAR model. This proposal represents a chemistry-based approach to assess hASBT functioning and complements ongoing biophysical studies. The long-term goal of this research is to use the developed 3D-QSAR model to rationally select parent drugs and their resulting prodrugs for successful hASBT targeting. This systematic and progressive approach will serve as a prototypical method to elucidate the substrate requirements of other solute carrier (SLC) proteins.

描述（由申请人提供）：几种溶质载体蛋白（SLC）在肠道中表达，以吸收营养物质和异种生物。尽管具有重要的生理意义，但载体蛋白尚未被系统地用作提高口服药物生物利用度的靶点。目前的建议旨在通过关注胃肠道中为数不多的药理学上重要的转运蛋白之一来缩小这一差距：人根尖钠依赖性胆汁酸转运蛋白（hASBT）。hASBT每天重吸收超过12克胆汁酸，这表明hASBT具有作为药物或前药吸收靶点的巨大能力。初步数据表明，药物可能与胆汁酸的C-24羧酸偶联，产生通过hASBT易位的前药，提高药物的生物利用度。使用靶向hASBT的前药，阿昔洛韦在大鼠体内的生物利用度提高了一倍。